Analyst Price Targets — GPCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 11:28 am | — | Canaccord Genuity | $111.00 | $52.62 | TheFly | Structure Therapeutics price target raised to $111 from $101 at Canaccord |
| June 11, 2026 10:42 am | Ananda Ghosh | H.C. Wainwright | $70.00 | $41.53 | StreetInsider | Structure Therapeutics (GPCR) PT Lowered to $70 at H.C. Wainwright |
| April 27, 2026 9:55 am | — | Canaccord Genuity | $101.00 | $45.49 | TheFly | Structure Therapeutics initiated with a Buy at Canaccord |
| March 17, 2026 12:29 pm | Evan Seigerman | BMO Capital | $145.00 | $56.88 | StreetInsider | Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital |
| January 20, 2026 12:20 pm | — | Guggenheim | $140.00 | $88.64 | TheFly | Structure Therapeutics price target raised to $140 from $90 at Guggenheim |
| January 19, 2026 10:26 pm | — | Goldman Sachs | $102.00 | $88.64 | TheFly | Structure Therapeutics moved to Buy rating at Goldman Sachs |
| December 19, 2025 1:43 pm | Ananda Ghosh | H.C. Wainwright | $90.00 | $66.45 | TheFly | Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright |
| December 12, 2025 1:10 pm | Terence Flynn | Morgan Stanley | $125.00 | $66.24 | TheFly | Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley |
| December 11, 2025 2:12 pm | — | Jefferies | $125.00 | $69.64 | TheFly | Structure Therapeutics price target raised to $125 from $79 at Jefferies |
| December 8, 2025 9:03 pm | — | Stifel Nicolaus | $90.00 | $69.98 | TheFly | Structure Therapeutics price target raised to $90 from $50 at Stifel |
Latest News for GPCR
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key…
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value…
Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for GPCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.